JUNS Jupiter Neurosciences Inc.

$JUNS This is comparable to APUS. Will do a +200% given the right PR. Similar OS and Float.

$JUNS $JUNS 🔥 FRESH CATALYST FROM 2 HOURS AGO 🔥 The news just dropped and the crowd hasn't realized what this actually means yet: 1️⃣ Major Clinical Milestone: First patient officially dosed in the Phase 2a RESET trial for Parkinson's Disease! 🧠💊 2️⃣ Strategic Options: The company has retained Tungsten Advisors to explore strategic alternatives and maximize shareholder value. (Translation in the biotech world: A potential buyout, merger, or strategic deal is being put on the table 👀💼) The real insanity? All of this is happening with a microscopic float of just 0.22M shares .

$JUNS $JUNS 🔥 FRESH CATALYST FROM 2 HOURS AGO 🔥 The news just dropped and the crowd hasn't realized what this actually means yet: 1️⃣ Major Clinical Milestone: First patient officially dosed in the Phase 2a RESET trial for Parkinson's Disease! 🧠💊 2️⃣ Strategic Options: The company has retained Tungsten Advisors to explore strategic alternatives and maximize shareholder value. (Translation in the biotech world: A potential buyout, merger, or strategic deal is being put on the table 👀💼) The real insanity? All of this is happening with a microscopic float of just 0.22M share

$JUNS 11:55 AM EDT, 10/06/2026 (MT Newswires) -- Jupiter Neurosciences (JUNS) said Tuesday it has started a process to evaluate strategic options, including sale or licensing, strategic partnerships, and business combinations. The firm said it has engaged Tungsten Advisors as its advisor in the plan to maximize shareholder value. It added that there can be no assurance that the process will result in any transaction.

Thank you . One of the best small-cap traders on stocktwits. Made $18K off his last call. Give him a follow.💯 Watching $JUNS & $JAGX 👀

$JUNS The rebound after noon's high volume is positive, showing a reversal to this down trend.

$JUNS commenced its Phase 2a RESET trial with the first Parkinson's patient dosed, marking a key clinical milestone.